lifestyle.buyersdesire.org

Author: ELI LILLY AND COMPANY

Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

March 19, 2026
Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

March 16, 2026
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

March 12, 2026
Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)

March 11, 2026
Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

March 10, 2026
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company

March 10, 2026
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

March 10, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies

March 9, 2026
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

February 4, 2026
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

January 30, 2026